StockData
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$13.04−0.46 (-3.41%)

Close on Nov 17, 2026Market cap $484.36MP/E –Yield –

Crescent Biopharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Crescent Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$72.68M. For fiscal 2025 it was -$71.53M. The highest annual figure on record is -$4.28M in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$71.53M–
FY2024Dec 31, 2024-$31.10M–
FY2023Dec 31, 2023-$34.88M–
FY2022Dec 31, 2022-$46.46M–
FY2021Dec 31, 2021-$57.49M–
FY2020Dec 31, 2020-$39.24M–
FY2019Dec 31, 2019-$51.98M–
FY2018Dec 31, 2018-$43.33M–
FY2017Dec 31, 2017-$29.77M–
FY2016Dec 31, 2016-$29.73M–
FY2015Dec 31, 2015-$8.24M–
FY2014Dec 31, 2014-$4.28M–
FY2013Dec 31, 2013-$15.54M–
FY2012Dec 31, 2012-$10.47M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.46M–
Q1 FY2026Mar 31, 2026-$8.94M–
Q4 FY2025Dec 31, 2025-$26.74M–
Q3 FY2025Sep 30, 2025-$17.54M–
Q2 FY2025Jun 30, 2025-$16.40M–
Q1 FY2025Mar 31, 2025-$10.85M–
Q4 FY2024Dec 31, 2024-$3.70M–
Q3 FY2024Sep 30, 2024-$7.99M–
Q2 FY2024Jun 30, 2024-$8.89M–
Q1 FY2024Mar 31, 2024-$10.51M–
Q4 FY2023Dec 31, 2023-$7.61M–
Q3 FY2023Sep 30, 2023-$8.68M–
Q2 FY2023Jun 30, 2023-$6.97M–
Q1 FY2023Mar 31, 2023-$11.61M–
Q4 FY2022Dec 31, 2022-$7.91M–
Q3 FY2022Sep 30, 2022-$8.62M–
Q2 FY2022Jun 30, 2022-$16.23M–
Q1 FY2022Mar 31, 2022-$13.70M–
Q4 FY2021Dec 31, 2021-$12.81M–
Q3 FY2021Sep 30, 2021-$16.95M–
Q2 FY2021Jun 30, 2021-$13.61M–
Q1 FY2021Mar 31, 2021-$14.13M–
Q4 FY2020Dec 31, 2020-$9.69M–
Q3 FY2020Sep 30, 2020-$11.50M–
Q2 FY2020Jun 30, 2020-$14.55M–
Q1 FY2020Mar 31, 2020-$3.50M–
Q4 FY2019Dec 31, 2019-$12.79M–
Q3 FY2019Sep 30, 2019-$13.45M–
Q2 FY2019Jun 30, 2019-$11.39M–
Q1 FY2019Mar 31, 2019-$14.35M–
Q4 FY2018Dec 31, 2018-$9.98M–
Q3 FY2018Sep 30, 2018-$10.08M–
Q2 FY2018Jun 30, 2018-$13.06M–
Q1 FY2018Mar 31, 2018-$10.21M–
Q4 FY2017Dec 31, 2017-$8.37M–
Q3 FY2017Sep 30, 2017-$6.23M–
Q2 FY2017Jun 30, 2017-$6.11M–
Q1 FY2017Mar 31, 2017-$9.06M–
Q4 FY2016Dec 31, 2016-$5.95M–
Q3 FY2016Sep 30, 2016-$7.47M–

More Crescent Biopharma figures

See a number that looks wrong?